CAS 312636-16-1|SKI II

Introduction：Basic information about CAS 312636-16-1|SKI II, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. SKI II BiologicalActivity
3. Chemical & Physical Properties
4. Safety Information
5. Articles5
6. Synonyms

Common Name	SKI II
CAS Number	312636-16-1	Molecular Weight	302.779
Density	1.4±0.1 g/cm3	Boiling Point	507.1±60.0 °C at 760 mmHg
Molecular Formula	C₁₅H₁₁ClN₂OS	Melting Point	/
MSDS	ChineseUSA	Flash Point	260.5±32.9 °C

Names

Name	4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol
Synonym	More Synonyms

SKI II BiologicalActivity

Description	SKI-II is a synthetic inhibitor of sphingosine kinase (SK) activity with IC50 of 78 μM for SK1 and 45 μM for SK2.IC50 value: 78/45 μM (SK1/2) [2]Target: SKin vitro: SKI II inhibits cell proliferation by suppressing the Wnt/β-catenin signaling pathway. SKI II also reduces the expression of c-Myc and cyclin D1, the downstream target genes of the Wnt signaling pathway. SKI II inhibits cell proliferation by suppressing the Wnt/β-catenin signaling pathway. SKI II promotes the degradation of β-catenin by enhancing Wnt5A. SKI II inhibits the proliferation of HepG2 cells by blocking the Wnt/β-catenin signaling pathway. [1]in vivo: SKI-II causes an irreversible inhibition of SK1 by inducing its lysosomal and/or proteasomal degradation. In the present study, SKI-II was administered 3-weekly i.p. to LDL-R-/- mice for 16 weeks at a dose previously demonstrated to reduce tumor growth in mice. Preliminary experiments revealed that a single administration of SKI-II produces a significant reduction of plasma S1P with the maximum (40%) observed 12 h after injection. [2]
Related Catalog	Signaling Pathways >>Immunology/Inflammation >>SPHKResearch Areas >>Cancer
References	[1]. Liu H, et al. SphK1 inhibitor SKI II inhibits the proliferation of human hepatoma HepG2 cells via the Wnt5A/β-catenin signaling pathway. Life Sci. 2016 Apr 15;151:23-9. [2]. Potì F, et al. SKI-II--a sphingosine kinase 1 inhibitor--exacerbates atherosclerosis in low-density lipoprotein receptor-deficient (LDL-R-/-) mice on high cholesterol diet. Atherosclerosis. 2015 May;240(1):212-5. [3]. Liu Y, et al. SKI-II reverses the chemoresistance of SGC7901/DDP gastric cancer cells. Oncol Lett. 2014 Jul;8(1):367-373.

Description

SKI-II is a synthetic inhibitor of sphingosine kinase (SK) activity with IC50 of 78 μM for SK1 and 45 μM for SK2.IC50 value: 78/45 μM (SK1/2) [2]Target: SKin vitro: SKI II inhibits cell proliferation by suppressing the Wnt/β-catenin signaling pathway. SKI II also reduces the expression of c-Myc and cyclin D1, the downstream target genes of the Wnt signaling pathway. SKI II inhibits cell proliferation by suppressing the Wnt/β-catenin signaling pathway. SKI II promotes the degradation of β-catenin by enhancing Wnt5A. SKI II inhibits the proliferation of HepG2 cells by blocking the Wnt/β-catenin signaling pathway. [1]in vivo: SKI-II causes an irreversible inhibition of SK1 by inducing its lysosomal and/or proteasomal degradation. In the present study, SKI-II was administered 3-weekly i.p. to LDL-R-/- mice for 16 weeks at a dose previously demonstrated to reduce tumor growth in mice. Preliminary experiments revealed that a single administration of SKI-II produces a significant reduction of plasma S1P with the maximum (40%) observed 12 h after injection. [2]

Related Catalog

Signaling Pathways >>Immunology/Inflammation >>SPHKResearch Areas >>Cancer

References

[1]. Liu H, et al. SphK1 inhibitor SKI II inhibits the proliferation of human hepatoma HepG2 cells via the Wnt5A/β-catenin signaling pathway. Life Sci. 2016 Apr 15;151:23-9.

[2]. Potì F, et al. SKI-II--a sphingosine kinase 1 inhibitor--exacerbates atherosclerosis in low-density lipoprotein receptor-deficient (LDL-R-/-) mice on high cholesterol diet. Atherosclerosis. 2015 May;240(1):212-5.

[3]. Liu Y, et al. SKI-II reverses the chemoresistance of SGC7901/DDP gastric cancer cells. Oncol Lett. 2014 Jul;8(1):367-373.

Chemical & Physical Properties

Density	1.4±0.1 g/cm3
Boiling Point	507.1±60.0 °C at 760 mmHg
Molecular Formula	C₁₅H₁₁ClN₂OS
Molecular Weight	302.779
Flash Point	260.5±32.9 °C
Exact Mass	302.028076
PSA	73.39000
LogP	3.91
Appearance of Characters	white solid
Vapour Pressure	0.0±1.4 mmHg at 25°C
Index of Refraction	1.709
InChIKey	ZFGXZJKLOFCECI-UHFFFAOYSA-N
SMILES	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1

Safety Information

Personal Protective Equipment	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
RIDADR	NONH for all modes of transport

Articles5

Sphingolipids are required for efficient triacylglycerol loss in conjugated linoleic Acid treated adipocytes.

PLoS ONE 10(4) , e0119005, (2015)

Conjugated linoleic acid (CLA) reduces adiposity in human and mouse adipocytes. This outcome is achieved through a variety of biological responses including increased energy expenditure and fatty acid...

Sphingosine-1-phosphate receptor 3 promotes leukocyte rolling by mobilizing endothelial P-selectin.

Nat. Commun. 6 , 6416, (2015)

Sphingosine-1-phosphate (S1P) participates in inflammation; however, its role in leukocyte rolling is still unclear. Here we use intravital microscopy in inflamed mouse cremaster muscle venules and hu...

Ginsenoside compound K inhibits angiogenesis via regulation of sphingosine kinase-1 in human umbilical vein endothelial cells.

Arch. Pharm. Res. 37(9) , 1183-92, (2014)

Ginsenoside compound K (CK) is a metabolite of the protopanaxadiol-type saponins of Panax ginseng C.A. Meyer (Araliaceae), has long been used to treat against the development of cancer, inflammation, ...

Synonyms

4-{[4-(4-Chlorophenyl)-1,3-thiazol-2-yl]amino}phenol

Phenol, 4-[[4-(4-chlorophenyl)-2-thiazolyl]amino]-

4-[[4-(4-Chlorophenyl)-2-thiazolyl]amino]phenol

4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol

Kinome_2076

Phenol (4-[[4-(4-chlorophenyl)-2-thiazolyl]amino]

SKI II

SphK-I2,Sphingosine Kinase Inhibitor 2

UUL

Recommended......